Navigation Links
New Study Reveals Limitations of a Complex and Challenging Global,Tuberculosis Drug Marketplace

e deaths among women than all other causes of maternal mortality combined and is the leading infectious cause of death in people with HIV/AIDS. The global economic toll of TB is at least $12 billion each year. The bacteria that cause TB, known as Mycobacterium tuberculosis (M.tb), can reside latent in the human body for many years, but once active, attack the respiratory system, and are easily spread through the air like the common cold -- by coughing and sneezing. The WHO estimates that one third of the world is infected with M.tb.

The last class of TB drugs was developed and approved in the 1960s, and the lengthy treatment (6-9 months) required by the old regimen is hindering the progress of TB control. Public health experts agree that a faster-acting TB cure would improve compliance, lower relapse rates, reduce the growth of drug resistant TB, reduce health care costs and save millions of lives. Novel new TB drugs also are needed to be compatible with antiretroviral drugs used to treat HIV for the rising number of those co-infected with TB and HIV, as well as to work against the deadly climb in drug resistant TB.

About the Global Alliance for TB Drug Development

The Global Alliance for TB Drug Development (TB Alliance) is a not-for- profit, product development partnership accelerating the discovery and/or development of new TB drugs that will shorten treatment, be effective against susceptible and resistant strains, be compatible with antiretroviral therapies for those HIV-TB patients currently on such therapies, and improve treatment of latent infection.

Working with public and private partners worldwide, the TB Alliance is leading the development of the most comprehensive portfolio of TB drug candidates in history, and is committed to ensuring that approved new regimens are affordable, adopted and available to those who need them.

The TB Alliance operates with funding from the Bill & Melinda Gates Foundation, Irish Aid, th
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:5/22/2013)... BOTHELL, Wash. and VANCOUVER, British Columbia ... OGXI ), a leader in the development of ... today announced that four trials of its investigational compounds, custirsen ... at the 49 th Annual Meeting of the American ... from May 31 – June 4. ...
(Date:5/21/2013)... Mass. , May 21, 2013  NxStage Medical, ... of innovative dialysis products, today announced that it has ... critical care and in-center products to DaVita, the kidney ... http://photos.prnewswire.com/prnh/20110503/MM94799LOGO ) For the use ... United States , NxStage has executed a second ...
(Date:5/21/2013)... 21, 2013   Regulus Therapeutics Inc . ( ... and development of innovative medicines targeting microRNAs, today announced ... Chief Operating Officer and Executive Vice President, Finance, will ... Annual Healthcare Conference on Wednesday, May 29, 2013 at ... the Westin Boston Waterfront Hotel. The presentation ...
Breaking Medicine Technology:OncoGenex Announces Multiple 'Trials in Progress' Presentations at the 2013 ASCO Annual Meeting 2OncoGenex Announces Multiple 'Trials in Progress' Presentations at the 2013 ASCO Annual Meeting 3OncoGenex Announces Multiple 'Trials in Progress' Presentations at the 2013 ASCO Annual Meeting 4OncoGenex Announces Multiple 'Trials in Progress' Presentations at the 2013 ASCO Annual Meeting 5NxStage Announces New Agreements with DaVita 2Regulus to Present at Deutsche Bank 38th Annual Healthcare Conference 2
... Concord Medical Services Holdings Limited ("Concord Medical" or ... operator of the largest network of radiotherapy and ... it has signed an Memorandum of Understating ("MOU") ... Electric International Operations Company, Inc. and GE Medical ...
... 2011 China Nuvo Solar Energy, Inc. (OTCQB: CNUV) ... with Tandem Receivable Solutions to a western distributorship. Tandem, ... committed to assisting the Company from sales through collections ... Tom Toland, CEO of SurgLine stated, "As business ...
Cached Medicine Technology:Concord Medical and GE Healthcare Sign MOU for Preferred Partnership in China 2China Nuvo Solar Target Acquisition SurgLine Announces Agreement With Western U.S. Distributor 2China Nuvo Solar Target Acquisition SurgLine Announces Agreement With Western U.S. Distributor 3
(Date:5/22/2013)... (PRWEB) May 22, 2013 Athletic-Minded ... and publishing company released today its 2013 U.S. ... business hotels received the company’s recommendation after ongoing ... anonymous personal tours by the editorial staff. ... lap pool, sport court, etc.), in-room workout choices, ...
(Date:5/21/2013)... 22, 2013 The University of Colorado’s ... with HEALTHY DINING to help Coloradans make healthier choices ... new program is called HEALTHY DINING IN COLORADO. ... already participating in Colorado. Restaurants will offer a selection ... emphasizing lean protein, vegetables, fruits, whole grains and unsaturated ...
(Date:5/21/2013)... (PRWEB) May 22, 2013 Swimsuit season is ... Cellulite Whisperer ® products has begun with a 35% discount. ... to estrogen. Many women get the dreaded cellulite even if ... beneath the skin where they have been stored as toxic ... are no easy fixes, a specific program that works to ...
(Date:5/21/2013)... Feed additives have now become an ... chain. Most of the feed additives are used in ... and powders. There are variety of feed additives available ... upon the type of animal and feed. Nutritional feed ... essential nutrition to the animal in order to gain ...
(Date:5/21/2013)... WASHINGTON (May 22, 2013)Today the George Washington ... Health Services (SPHHS) announced the launch of ... Immigrant/Refugee Health, a collaboration between SPHHS, the ... and other community partners. This university-community partnership ... disproportionately affect Latino communities through research, mutual ...
Breaking Medicine News(10 mins):Health News:2013: The 10 Healthiest Business Hotels in the U.S. 2Health News:Colorado Takes a Huge Step toward Transforming the Family Dining Experience 2Health News:Colorado Takes a Huge Step toward Transforming the Family Dining Experience 3Health News:Diminish Cellulite for Swimsuit Season; Sublime Beauty Introduces Cellulite Whisperer® Products in the "Get Ready for Summer Sale" 2Health News:Protease Leads Feed Enzyme Market as Compared to Phytase & NSP Says New Research Report at ReportsnReports.com 2Health News:Protease Leads Feed Enzyme Market as Compared to Phytase & NSP Says New Research Report at ReportsnReports.com 3Health News:Protease Leads Feed Enzyme Market as Compared to Phytase & NSP Says New Research Report at ReportsnReports.com 4Health News:GW launches center to address health disparities in the Latino immigrant community 2Health News:GW launches center to address health disparities in the Latino immigrant community 3
... brain activity in children's with autism and found ... children. The Researchers found //that the autism children's had ... observation and imitating others action and expressing facial response. ... Nature Neuroscience. ,Autism is a developmental disorder ...
... habits and increased weight in the middle school students reports ... employment of food as motivation resulted in an increase in ... food and organizing fund raising programs with food as a ... About two thirds of adults and on third of children ...
... on behalf of the HIV positive people of Mizo society to ... Malsawmdawnga who is the president of Mizoram People Living With AIDS// ... world is changing for the better and awareness about AIDS is ... up. ,He condemned the practice of sealing the ...
... the press about improvising the health care facilities at Patna ... more hospitals with ICUs// and ambulance facilities 24-hour health care ... , ,He put forth the idea about giving certain ... He also mentioned that the chief minister Mr. Nitish Kumar ...
... in India has called for curtailing comparative advertisements, after ... should be made to the Code for Commercial Advertising ... and the Monopolies and Restrictive Trade Practices Act in ... in some western nations where advertisements attacking the products ...
... Bhopal: The 21st anniversary of the Bhopal gas leak tragedy ... and Research Center resigned. , ,The doctors wanted a ... visit for treatment daily. Run by a trust, the BMHRC ... Apart from the survivors of the gas victims, it also ...
Cached Medicine News:Health News:Conditions Of The HIV/AIDS Patients In The Mizo Society 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: